PAM
CPRX icon

PVG Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

PVG Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,786
Closed -$183K – 48
2024
Q2 		$183K Buy
+11,786
New +$183K 0.72% 33
2023
Q4 		$296K Buy
+17,595
New +$241K 1.43% 17

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

PVG Asset Management's CPRX Position: Q3 2024 in Review

PVG Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2024, closing a stake of 11,786 shares — an estimated $183K sold.

PVG Asset Management first reported a position in CPRX in Q4 2023 and held it in 2 quarters. The position peaked at $296K in Q4 2023. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

  • PVG Asset Management reported no remaining Catalyst Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • PVG Asset Management sold 11,786 Catalyst Pharmaceutical shares in Q3 2024, an estimated $183K.
  • PVG Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2023 and held it in 2 quarters.
  • PVG Asset Management's Catalyst Pharmaceutical position peaked at $296K in Q4 2023.
  • 316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on PVG Asset Management's 13F filing for Q3 2024, filed 25 Nov 2024.